Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

Bain Capital, an investment firm that has spread ... and diabetes and metabolic disease. The unit’s top-selling product is the amyotrophic lateral sclerosis drug Radicava, which accounted ...

Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.

Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...

The provider of highly-engineered processing equipment and solutions will sell a 51% stake in the injection molding and extrusion business for $287 million.

Bain Capital is in talks to acquire Mitsubishi Chemical Group’s41880.31%increase; green up pointing triangle pharmaceutical business in a potential multibillion-dollar deal, a person familiar ...

Tokyo, Feb. 7 (Jiji Press)--Mitsubishi Chemical Group Corp. said Friday that it will sell subsidiary Mitsubishi Tanabe Pharma Corp. to U.S. investment firm Bain Capital LP. for about 510 billion yen.

The American investment company Bain Capital is considering the sale of Italmatch Chemicals SpA, an Italian manufacturer of specialty chemicals. This is reported in a press release from Bain Capital.

Mitsubishi Chemical, a Japanese corporation has agreed to sell its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, to U.S. private equity firm Bain Capital, according to Reuters on Friday.

TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately ...